Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2010 February 1; 120(2): 401–403.
Published online 2010 January 25. doi:  10.1172/JCI42088
PMCID: PMC2810093

The role of genetic diversity in cancer


The role of genetic heterogeneity within neoplasms is increasingly recognized as important for understanding the dynamics of cancer progression, cancer stem cells, and therapeutic resistance, and there is interest in intratumoral heterogeneity measurements as potential biomarkers for risk stratification. In this issue of the JCI, Park et al. characterize this genetic diversity in carcinoma in situ and in invasive regions from 3 types of human breast cancers and lay the groundwork for translation of these measures to the clinic.

Although there are clear suggestions that diversity may be important in the establishment and progression of cancers (1), it is unclear how diversity should be defined. Should we use genetic or phenotypic markers? How can we account for epigenetic diversity? Should we look at large samples or small ones, and how many biopsies should we sample in order to accurately estimate the underlying diversity of the neoplasm? The problems of defining diversity and characterizing the number of cancer clones are not new and have parallels to problems encountered in other fields. Ecologists have created various measures to estimate the number and abundance of species (2); even in literature, calculating the number of words Shakespeare knew from his existing corpus (3) is analogous to determining the number of cancer clones in a tumor from a small number of samples. Heterogeneity in neoplasms has long been recognized (47), but has only recently been systematically investigated, and much can be gained by applying these methodologies to cancer and precancerous lesions (810). As Park et al. clearly demonstrate in their study in this issue of the JCI (11), this is not merely an academic exercise, as the level of heterogeneity in a neoplasm may have important clinical implications as a biomarker of risk stratification.

Genetic diversity as a biomarker

It is important to note that measures of genetic or epigenetic diversity are a novel form of biomarker. Most previous biomarkers in cancer measure the presence of an abnormality, like loss of heterozygosity (LOH) in the tumor suppressor TP53 (12), amplification of the tyrosine kinase receptor HER2, or the level of some mRNA or protein, such as prostate-specific antigen (13). In contrast, by measuring genetic diversity, we are measuring a parameter of the underlying dynamics driving neoplastic progression, regardless of the particular loci in question. Because neoplastic progression is a process of somatic evolution, in which genetic and epigenetic alterations generate diversity, and ecological interactions like competition between clones lead to natural selection among that diversity, the generation and maintenance of diversity in heritable alterations, such as genetic and epigenetic changes, determines the rate of somatic evolution. Thus, it is possible to gather information on the rate of progression even if we do not know the specific tumor suppressor genes and oncogenes (i.e., driver mutations) that provide fitness benefits to neoplastic clones in a given organ. Other measures of the rate of somatic evolution, such as mutation rate, population size of self-renewing cells, and generation time, should also be robust and general biomarkers of progression (14).

We have previously shown that genetic clonal diversity is predictive of progression in a precancerous lesion (10). In their current study, Park et al. extended this idea to cancers, characterizing heterogeneity from 4 samples from each of 15 human breast cancer lesions, including a mix of ductal carcinoma in situ (DCIS; the most common type of noninvasive breast cancer) and invasive regions (11). They report a high level of heterogeneity within the tumor samples, and their analyses hint that measurements of the diversity in one phenotypic subpopulation (CD24+ cells in DCIS) may be a useful predictor of a variety of histopathological characteristics, such as tumor stage, presence of intratumoral and/or peritumoral DCIS, and estrogen receptor (ER) status. ER status is important because ER+ tumors tend to be responsive to selective ER modulators, such as tamoxifen and raloxifene. Thus, it is possible that a single diversity measure could provide a snapshot of a variety of tumor processes. Surprisingly, they also found that diversity in DCIS and invasive regions is similar, which suggests that diversity does not increase in a systematic manner as the neoplasm becomes invasive. These studies together suggest that measurements of diversity may be clinically important at all phases of disease progression. The studies have used different types of lesions to measure diversity: microsatellite shifts, LOH, mutation, methylation, and copy number variation measured by FISH (as in our previous work; see ref. 10). The fact that clinically relevant information can be extracted from diversity measures based on such a variety of markers implies that diversity measurements are potentially robust biomarkers.

Cancer stem cells or independent clones?

The present study by Park et al. extends previous work of the Polyak lab (15) questioning the cancer stem cell paradigm in breast cancers, an idea that has important implications for the evolutionary dynamics in neoplastic progression. The cancer stem cell hypothesis posits that only a minority of cells in a neoplasm are self-renewing and are responsible for the long-term propagation of the neoplasm, analogous to stem cells in normal tissues. In breast cancer, CD44 has been proposed as a marker of breast stem cells, while CD24+ cells are thought to derive from the CD44+ cell population. In their study, Polyak et al. found a clone in the CD24+ population not present in the CD44+ population (15), which suggests that the cancer stem cell and linear differentiation model is inaccurate in this case. If CD24+ cells have only diverged from CD44+ cells for a few cell divisions, then the CD44+ and CD24+ cells should have essentially the same genetic diversity (Figure (Figure1).1). In the current study, Park et al. found that diversity generally differs, sometimes dramatically, between CD24+ and CD44+ cells (see Figure 5A in ref. 11). Either the linear differentiation model needs to be reevaluated, or we need to develop better markers of breast cancer stem cells. The authors also found diversity differences between cells in invasive and DCIS areas, although it can be difficult to interpret this in relation to the cancer stem cell hypothesis. If the stem cell pool is large enough (16) or the mutation rate high enough, a neoplasm might contain a highly diverse pool of cells.

Figure 1
For neoplasms maintained by stem cells, somatic evolution will be dominated by evolution within the stem cell compartment.

The cancer stem cell hypothesis and the theory of clonal evolution are not mutually exclusive (Figure (Figure1).1). The presence of cancer stem cells simply moves the dynamics of evolution from the cancer cell population as a whole to the stem cell compartment. Thus, clonal expansion and competition would occur within the stem cell pool. This may make genetic drift (i.e., stochastic changes in mutation frequency) a more important process in neoplastic progression when the total pool of evolving cells is small. The dynamics of putative cancer stem cell compartments are largely unknown. If a stem cell pool is to expand, stem cells must divide symmetrically at least some of the time and either replace slower-dividing cells or expand the population size of the stem cell compartment. We do not yet know whether the putative stem cell pool in a neoplasm acts as a single population or if there exists a variety of potentially cooperative or competitive subpools of stem cells. Stem cell–like behavior may also be a product of the microenvironment, and the feedback between microenvironment and cancer initiation, invasion, and metastasis is an area of active study (17, 18).

Open questions

To our knowledge, measures of heterogeneity have not been systematically studied in cancer itself until now. Several key areas remain unexplored. Most importantly, the relationship between diversity measurements in cancer samples and survival has yet to be systematically investigated. Our previous study demonstrated a link between progression and diversity in precancerous esophageal neoplasms (10), but it is difficult to measure most tumors in their precancerous states. With only a small number of samples, the data reported by Park et al. hints at a link between diversity and histopathology (11), but this needs to be evaluated in a larger sample pool and correlated with longitudinal follow-up, including treatment outcome. A second key area yet to be examined is the relationship between genetic diversity and therapeutic resistance. In studying resistance, we are battling the underlying evolutionary forces that lead to diversity in a cancer, the interplay between mutation and selection. It is clear that therapy can select for the expansion of rare clones (19, 20). Logic would suggest that more heterogeneous cancers are more likely to harbor one of these resistance mutations, but this has yet to be demonstrated. Finally, determining the best measures of heterogeneity and loci must take into account their robustness as biomarkers and ease of clinical translation.

The study presented here (11) provides a glimpse of the high level of genetic heterogeneity found in stem cell–like and more differentiated populations from invasive and in situ breast cancer lesions. This should be the first of many such studies to elucidate the role and dynamics of diversity within neoplasms.


This work was supported in part by the Commonwealth Universal Research Enhancement Program, Pennsylvania Department of Health; the Pew Charitable Trust; the Martha W. Rodgers Charitable Trust; the Landon AACR Innovator Award for Cancer Prevention; and NIH grants R03 CA137811, P01 CA91955, P30 CA010815, F32 CA132450, and R01 CA140657.


Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2010;120(2):401–403. doi:10.1172/JCI42088.

See the related article beginning on page 636.


1. Heng HH, et al. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol. 2006;208(2):461–472. doi: 10.1002/jcp.20685. [PubMed] [Cross Ref]
2. Magurran AE.Measuring Biological Diversity . Malden, MA: Blackwell Publishing; 2004.
3. Efron B, Thisted R. Estimating the number of unseen species: How many words did Shakespeare know? Biometrika. 1976;63:435–447.
4. de Grouchy J, de Nava C, Cantu JM, Bilski-Pasquier G, Bousser J. Models for clonal evolutions: a study of chronic myelogenous leukemia. Am J Hum Genet. 1966;18(5):485–503. [PubMed]
5. Ford CE, Clarke CM. Cytogenetic evidence of clonal proliferation in primary reticular neoplasms. Can Cancer Conf. 1963;5:129–146. [PubMed]
6. Dawe CJ. Phylogeny and oncogeny. Natl Cancer Inst Monogr. 1969;31:1–40. [PubMed]
7. Yosida TH. Relation between chromosomal alteration and development of tumors. Jpn J Genet. 1966;41:439–451. doi: 10.1266/jjg.41.439. [Cross Ref]
8. Siegmund KD, Marjoram P, Woo YJ, Tavare S, Shibata D. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc Natl Acad Sci U S A. 2009;106(12):4828–4833. doi: 10.1073/pnas.0810276106. [PubMed] [Cross Ref]
9. Tsao JL, Tavare S, Salovaara R, Jass JR, Aaltonen LA, Shibata D. Colorectal adenoma and cancer divergence. Evidence of multilineage progression. Am J Pathol. 1999;154(6):1815–1824. [PubMed]
10. Maley CC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38(4):468–473. doi: 10.1038/ng1768. [PubMed] [Cross Ref]
11. Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010;120(2):636–644. doi: 10.1172/JCI40724. [PMC free article] [PubMed] [Cross Ref]
12. Galipeau PC, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67. doi: 10.1371/journal.pmed.0040067. [PMC free article] [PubMed] [Cross Ref]
13. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845–856. doi: 10.1038/nrc1739. [PubMed] [Cross Ref]
14. Pepper J, Findlay CS, Kassen R, Spencer S, Maley C. Cancer research meets evolutionary biology. Evolutionary Applications. 2009;2(1):62–70. doi: 10.1111/j.1752-4571.2008.00063.x. doi:10.1111/j.1752-4571.2008.00063.x. [PMC free article] [PubMed] [Cross Ref]
15. Shipitsin M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259–273. doi: 10.1016/j.ccr.2007.01.013. [PubMed] [Cross Ref]
16. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456(7222):593–598. [PMC free article] [PubMed]
17. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev. 2008;18(1):27–34. doi: 10.1016/j.gde.2007.12.006. [PMC free article] [PubMed] [Cross Ref]
18. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–273. [PubMed]
19. Roche-Lestienne C, Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol. 2003;40(2 Suppl 2):80–82. [PubMed]
20. Shah NP, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. . J Clin Invest. 2007;117(9):2562–2569. doi: 10.1172/JCI30890. [PubMed] [Cross Ref]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation